Clinical trials: Ankylosing Spondylitis (AS)
- Condition Ankylosing Spondylitis (AS)
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Rheumatoid Arthritis (RA), Atopic Dermatitis (AD)
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases.
- Conditions
- Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
- Trial name
- NCT04541810
- Where
- 116 sites in South Korea
- Volunteers
- 2,369 people
- Sponsor
- AbbVie
Ankylosing Spondylitis
Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)
This study is a population-based cohort of patients with ankylosing spondylitis (AS) from general medical practices in the UK, France, and Germany with a nested case control component to assess associations between drug exposures…
- Trial name
- NCT01077843
- Testing
- Etoricoxib, Other Cox-2 inhibitors, Other Non-selective NSAIDs
- Volunteers
- 27,381 people
- Sponsor
- Organon and Co
Spondylarthropathies; Spondylitis, Ankylosing
Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)
The study is intended to provide additional post-marketing safety data regarding the use of etoricoxib for the indication of ankylosing spondylitis.
- Trial name
- NCT01327638
- Testing
- etoricoxib, Other COX-2 inhibitor, nsNSAIDs
- Volunteers
- 21,108 people
- Sponsor
- Organon and Co